Stock Ratings / Health Care / IRWD / earnings

CRMD (62) CLYM (38) NVCT (43) GERN (37) ⌘ Pro Terminal →

Ironwood Pharmaceuticals Inc. (Class A) (IRWD) Next Earnings Date & Expected ±10.1% Move

$3.62 +0.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Ironwood Pharmaceuticals Inc. (Class A) (IRWD) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $598.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRWD)Realized 20D OHLCV Swing Band: ±10.1%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±10.1% Swing Band

±$0.37 Expected Swing

MODEL EARNINGS SETUP GAUGE

IRWD Quantitative Pre-Earnings Setup: 69/100

Trailing EPS: $0.15 • YoY Revenue Growth: -15.7%

Model Bullish Setup (69/100)Model Risk Weight (31/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$296.2M	$24.0M	$127.0M	52%
FY 2024	2024-12-31	$351.4M	$880.0K	$103.4M	52%
FY 2023	2023-12-31	$442.7M	-$1.03B	$183.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating IRWD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on IRWD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IRWD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.35%📐 HORIZONTAL RANGE

2026-10-30O $3.59H $3.64L $3.45C $3.62VOL 1.47M

RES: $4.61SUP: $3.37SMA50: $3.96SMA200: $3.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRWD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRWD Butterfly Map → + Track IRWD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.6%/yr Implied 5Y Growth

vs. -15.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRWD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRWD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IRWD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRWD)

Health Care Rank #102 of 1016 ⚔️ CRMD vs IRWD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRWD vs. CRMD, CLYM, NVCT, GERN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ironwood Pharmaceuticals Inc. (Class A) (IRWD) ranks #102 by composite RQD confidence (69/100, grade C+) and #420 by equity capitalization ($598.2M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IRWD ACTIVE Ironwood Pharmaceuticals Inc. (Class A)	C+	69/100	24.9x	—	85.0%	+0.28%	$598.2M	Benchmark Subject
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-6.83%	$595.5M	/crmd-vs-irwd →
CLYM Climb Bio Inc.	D-	38/100	—	—	-35.0%	+2.08%	$593.3M	/clym-vs-irwd →
NVCT Nuvectis Pharma Inc.	D-	43/100	—	—	-35.0%	+1.14%	$605.6M	/nvct-vs-irwd →
GERN Geron Corporation	D-	37/100	—	—	-20.2%	-2.30%	$607.9M	/gern-vs-irwd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001446847

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ironwood Pharmaceuticals Inc. (Class A) (IRWD) reported GAAP revenue of $296.2M (-15.7% vs. FY2024 revenue of $351.4M , and -33.1% cumulative change since FY2023) , GAAP net income of $24.0M, operating cash flow of $127.0M, and free cash flow of $127.0M (+22.8% YoY). On the balance sheet, IRWD closed FY2025 with $396.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$296.2M	$24.0M	$127.0M	$127.0M	$396.9M	—
FY2024 (FY)	2024-12-31	$351.4M	$880.0K	$103.5M	$103.4M	$350.9M	—
FY2023 (FY)	2023-12-31	$442.7M	-$1.03B	$183.4M	$183.4M	—	—

3. IRWD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ: IRWD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $3.62 (+0.28% 1D, market cap $598.2M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, IRWD ranks #102 in composite RQD confidence.

How does IRWD compare to CRMD and CLYM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRWD carries a Roarable C+ (69/100 RQD), trailing P/E of 24.9x, gross margin of —, and ROIC of 85.0%. By comparison, CRMD (CorMedix Inc.) holds a C grade (62/100 RQD, P/E 3.7x, ROIC 45.5%, cap $595.5M) and CLYM (Climb Bio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $593.3M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRWD?

Per IRWD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001446847), Ironwood Pharmaceuticals Inc. (Class A) generated $296.2M in revenue (-15.7% YoY), $24.0M in net income, and $127.0M in free cash flow against $396.9M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRWD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRWD last traded at $3.62 (+0.28% on volume of 1,367,784 shares), positioning the stock -8.59% below its 50-day simple moving average ($3.96) and -9.27% below its 200-day simple moving average ($3.99). Across its 52-week range of $1.76 to $5.78, IRWD sits at the 46.3% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($3.25 to $3.99).